Vanda Pharmaceuticals and the FDA have agreed to lay down their swords, squashing years of legal disputes with an agreement that will see regulatory action on much of Vanda’s grievances. The ...
Once again, Vanda Pharmaceuticals is challenging the FDA in court. This time, the company says the agency failed to give its application for Hetlioz in jet lag disorder a proper hearing after the FDA ...
WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the J.P. Morgan ...
Vanda Pharmaceuticals (VNDA) announced the submission of a Biologics License Application, BLA, to the U.S. Food and Drug Administration, FDA, for ...
Vanda Pharmaceuticals has failed to persuade the FDA to approve its gastroparesis candidate on the strength of a phase 3 trial that missed its primary endpoint. The biotech came out swinging after the ...
Vanda Pharmaceuticals has agreed to a plan in which the Food and Drug Administration will conduct more reviews of two of its drugs to resolve disputes between the company and the agency. Under the ...
Vanda Pharmaceuticals shares rose after the company said it had submitted a biologics license application to the Food and Drug Administration for its generalized pustular psoriasis treatment. The ...
Vanda Pharmaceuticals stands at a pivotal point, leveraging strong Fanapt growth and a robust late-stage pipeline for future expansion. VNDA's aggressive investment in commercial infrastructure has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback